

World Journal of *Transplantation*

World J Transplant 2022 January 18; 12(1): 1-20



OPINION REVIEW

- 1 Human pegivirus infection after transplant: Is there an impact?

Mrzljak A, Simunov B, Balen I, Jurekovic Z, Vilibic-Cavlek T

CASE REPORT

- 8 Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report

Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML

- 15 Is *de novo* membranous nephropathy suggestive of alloimmunity in renal transplantation? A case report

Darji PI, Patel HA, Darji BP, Sharma A, Halawa A

ABOUT COVER

Associate Editor of *World Journal of Transplantation*, Maria Irene Bellini, MD, PhD, FEBS (Transplant), Assistant Professor, Department of Surgical Sciences, Quarta Clinica Chirurgica, Sapienza University, Roma 00161, Italy. mariairene.bellini@uniroma1.it

AIMS AND SCOPE

The primary aim of *World Journal of Transplantation* (*WJT*, *World J Transplant*) is to provide scholars and readers from various fields of transplantation with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJT mainly publishes articles reporting research results obtained in the field of transplantation and covering a wide range of topics including bone transplantation, brain tissue transplantation, corneal transplantation, descemet stripping endothelial keratoplasty, fetal tissue transplantation, heart transplantation, kidney transplantation, liver transplantation, lung transplantation, pancreas transplantation, skin transplantation, etc..

INDEXING/ABSTRACTING

The *WJT* is now abstracted and indexed in PubMed, PubMed Central, Scopus, China National Knowledge Infrastructure (CNKI), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Lin-YuTong Wang*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ping Yan*.

NAME OF JOURNAL

World Journal of Transplantation

ISSN

ISSN 2220-3230 (online)

LAUNCH DATE

December 24, 2011

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Maurizio Salvadori, Sami Akbulut, Vassilios Papalois, Atul C Mehta

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3230/editorialboard.htm>

PUBLICATION DATE

January 18, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Human pegivirus infection after transplant: Is there an impact?

Anna Mrzljak, Bojana Simunov, Ivan Balen, Zeljka Jurekovic, Tatjana Vilibic-Cavlek

ORCID number: Anna Mrzljak 0000-0001-6270-2305; Bojana Simunov 0000-0002-1768-2277; Ivan Balen 0000-0002-7071-539X; Zeljka Jurekovic 0000-0003-0690-2577; Tatjana Vilibic-Cavlek 0000-0002-1877-5547.

Author contributions: Mrzljak A made contributions to the concept and design the manuscript; Mrzljak A, Simunov B, Balen I, and Vilibic-Cavlek T were involved in writing the manuscript; Jurekovic Z critically revised the manuscript; and all authors approved the final manuscript.

Conflict-of-interest statement: The authors declare no conflict of interest for this article.

Supported by the Croatian Science Foundation, Emerging and Neglected Hepatotropic Viruses after Solid Organ and Hematopoietic Stem Cell Transplantation, No. IP-2020-02-7407.

Country/Territory of origin: Croatia

Specialty type: Transplantation

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Anna Mrzljak, Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb 10000, Croatia

Bojana Simunov, Zeljka Jurekovic, Department of Medicine, Merkur University Hospital, Zagreb 10000, Croatia

Ivan Balen, Department of Gastroenterology and Endocrinology, General Hospital "Dr. Josip Bencevic", Slavonski Brod 35000, Croatia

Tatjana Vilibic-Cavlek, Department of Virology, Croatian Institute of Public Health, School of Medicine, University of Zagreb, Zagreb 10000, Croatia

Corresponding author: Anna Mrzljak, FEBG, PhD, Associate Professor, Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Kispaticeva ulica 12, Zagreb 10000, Croatia. anna.mrzljak@gmail.com

Abstract

The microbiome's role in transplantation has received growing interest, but the role of virome remains understudied. Pegiviruses are single-stranded positive-sense RNA viruses, historically associated with liver disease, but their pathogenicity is controversial. In the transplantation setting, pegivirus infection does not seem to have a negative impact on the outcomes of solid-organ and hematopoietic stem cell transplant recipients. However, the role of pegiviruses as proxies in immunosuppression monitoring brings novelty to the field of virome research in immunocompromised individuals. The possible immunomodulatory effect of pegivirus infections remains to be elucidated in further trials.

Key Words: Virome; Human pegivirus; Epidemiology; Solid-organ transplant; Hematopoietic stem cell transplantation

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Pegiviruses are single-stranded positive-sense RNA viruses, historically associated with liver disease, but their pathogenicity is controversial. Pegivirus infection does not seem to have a negative impact on the outcome of solid-organ and hematopoietic stem cell transplant recipients. However, the role of pegiviruses as proxies in immunosuppression monitoring brings novelty to the field of virome research in immunocompromised individuals.

Grade B (Very good): B, B
 Grade C (Good): 0
 Grade D (Fair): 0
 Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Received: January 31, 2021

Peer-review started: January 31, 2021

First decision: October 17, 2021

Revised: October 25, 2021

Accepted: January 6, 2022

Article in press: January 6, 2022

Published online: January 18, 2022

P-Reviewer: Chan WYK, Zhou S

S-Editor: Wang JJ

L-Editor: Wang TQ

P-Editor: Wang JJ



Citation: Mrzljak A, Simunov B, Balen I, Jurekovic Z, Vilibic-Cavlek T. Human pegivirus infection after transplant: Is there an impact? *World J Transplant* 2022; 12(1): 1-7

URL: <https://www.wjgnet.com/2220-3230/full/v12/i1/1.htm>

DOI: <https://dx.doi.org/10.5500/wjt.v12.i1.1>

INTRODUCTION

The microbiome's role in transplantation has received growing interest, but the role of virome remains understudied. Several studies have shown that the virome changes upon immunosuppression initiation[1,2]. Most notable is the increase in the anelloviruses but also in pegiviruses.

Pegiviruses are single-stranded positive-sense RNA viruses, most closely related to hepatitis C virus (HCV) in terms of genome organization with structural genes located at the 5' genomic region and non-structural genes at the 3' end[3]. The genome encodes a polyprotein that is co- and post-translationally cleaved into individual viral proteins. Structural proteins common to all pegiviruses are the envelope glycoproteins (E1 and E2), and non-structural proteins are NS2-NS5B[4]. Pegiviruses are classified into eleven species (pegivirus A-K) within the genus *Pegivirus* in the *Flaviviridae* family. Two pegiviruses are known to infect humans, the human pegivirus (HPgV) and the HPgV-2, but their pathogenicity is limited and no clear association with any human disease has been established[5].

HPgV was discovered in 1995 from the sera of patients with hepatitis by two independent investigator groups, who named it GB virus C and hepatitis G virus (HGV), respectively. The HPgV's E2 glycoprotein, involved in the adhesion and fusion with the host cells, targets the production of anti-HPgV antibodies, which appear after the viral clearance and provide partial protection against reinfection[6]. The virus is efficiently transmitted through sexual contact and intravenous substance use, vertically from mother to child, and through exposure to infected blood and blood components[7].

Available data suggest a high prevalence of HpgV viremia (> 40%) in populations with parenteral exposure risk[8]. Although early studies indicated that the HPgV is hepatotropic, numerous subsequent studies have shown that HPgV is rarely detectable in infected individuals' liver tissue. In addition, no evidence of a liver disease potentially linked to HPgV was observed during the follow-up of different patient categories[7].

HPgV-2 was isolated in 2015 from the plasma of HCV-infected patients with multiple blood-borne exposures in the United States[8]. A low prevalence of HPgV-2 viremia has been noted in the general population, but there is an increase in patients with HCV infection and injecting drug users co-infected with HCV[9]. Further studies indicated that HPgV-2 is a lymphotropic but not a hepatotropic virus, which may explain the lack of association with liver disease[10].

HPgVs are distributed globally, and viral RNA is present in roughly 750 million people[6], making it ubiquitous in human populations. The prevalence of HPgV viremia from cross-sectional studies of healthy blood donors in developed countries ranges between 1% and 5%. Nearly 200000 units of HPgVs-contaminated blood products are transfused each year in the United States[11]. In comparison, in developing countries, up to 20% of blood donors have an active infection[12]. Data suggest that approximately 1.5-2.5 billion people are currently infected or have evidence of prior HPgV infection[6].

Numerous studies examined the presence of HPgV in several countries. Generally, a high HPgV prevalence is observed among subjects with parenteral exposure, including those exposed to blood and blood products, those on hemodialysis, those with a history of intravenous substance use, and patients with chronic hepatitis C or human immunodeficiency virus (HIV) infection[13].

HPGV AFTER TRANSPLANTATION OF SOLID ORGANS AND NON-SOLID ORGANS

HPgVs have received much attention due to the possible beneficial immunomodulatory effects by reducing immune activation in patients with other viral diseases such as HIV infection, hepatitis B, and Ebola virus disease[14-17]. On the other hand, HPgV

viremia has also been associated with the development of non-Hodgkin lymphoma (NHL). HPgV is a lymphotropic virus that may cause persistent infection in T and B lymphocytes, reduced Fas-mediated apoptosis, and impaired T cell and interleukin-2 receptor signaling[18]. HPgV infection anticipates the development of NHL by several years and resolved infection was not associated with NHL risk[19]. Pegiviruses have been studied both in hematopoietic stem cell transplantation (HSCT) and solid-organ transplant (SOT) recipients (Table 1).

Studies in HSCT recipients are limited. The prevalence of HPgV in HSCT patients ranges from 18.6%, as described in the study from Switzerland[20], to almost 30% in an earlier French study[21]. As in the general population, the risk of viremia rises with the number of received blood products[20,22]. No significant influence of pegiviruses on HSCT patient outcomes was found. On the other hand, no beneficial effect of pegivirus infections is currently proven; therefore, some studies warrant HPgV donor screening for blood products used in HSCT recipients until more conclusive studies are performed[22].

Early studies in SOT recipients were done mostly in liver transplant (LT) recipients, due to the presumed hepatotropic nature of the virus, all showing a high prevalence but no significant influence on patient outcomes[23-26]. The largest of the studies included in this review is the recent Japanese study on 313 LT recipients. This monocentric study showed an increased prevalence of HPgV in LT recipients compared to hepatectomy controls[27]. As in the earlier studies, there was no significant association between HPgV infection and LT outcomes. The study showed that HPgV infection induced the up-regulation of interferon-stimulated gene (ISG) expression in peripheral blood mononuclear cells[27].

HPgV is transmitted through parenteral, sexual, and perinatal routes[28]. Parenterally exposed individuals such as hemodialysis patients, therefore, have a higher risk of infection. An Indian study using univariate analysis showed that the prevalence of GB virus C/HGV RNA was significantly associated with ≥ 20 hemodialysis sessions[29]. After the transition from dialysis, the prevalence remains high in kidney transplant (KT) recipients, ranging from 12% to 47% in different countries[30-33]. A large Italian study in KT recipients ($n = 155$) showed an HGV RNA and anti-HGV prevalence of 24% and 17%, respectively[34]. None of the studies above, found any influence on patient outcomes, including kidney or liver function. On the other hand, the largest study in KT recipients (Germany, $n = 221$)[33] showed that a much higher proportion of KT recipients were exposed to HGV, than that suggested by HGV RNA detection alone. The prevalence of HGV RNA and anti-HGV in the study was 14% and 40%, respectively. Most infected individuals eliminate the virus over time. Unfortunately, the majority of other studies did not include serological analyses. Most of the studies on HPgV were done immediately after the discovery of the virus, focusing mostly on hepatic function or the function of the transplanted organ. Only the most recent study[1] tried to include other post-transplant complications in the analysis, *e.g.*, new-onset diabetes after transplantation or nephrotoxicity in LT recipients. The study highlighted a potential use of anellovirus infection as a proxy for determining the immunological status. At the moment there is no standard way to measure total immunosuppression, besides the widely available through levels of immunosuppressant drugs. In the same study, all of the HPgV positive participants were still alive 5 years after LT, indicating a protective role of HPgV in post-transplantation survival[1].

The paucity of other SOT recipient studies probably reflects the proportionately lower number of those transplants performed. We found no studies evaluating HPgV in simultaneous pancreas-kidney transplantations or lung transplant recipients. The studies in heart transplant recipients are concordant to those in other SOT, showing no adverse outcome but a high HPgV prevalence, up to 36%[35-42].

CONCLUSION

To conclude, pegivirus infection does not seem to have a negative impact on the outcome of transplant recipients. Nevertheless, studies are limited and lacking prospective data. What remains to be elucidated is the possible immunomodulatory effect of pegivirus infections. Also, the role of pegiviruses as proxies in immunosuppression monitoring brings novelty to the field of virome research in immunocompromised individuals. The subject deserves further research and evaluation.

Table 1 Seroprevalence and RNA prevalence studies in different transplant populations

Type of transplant and period	Country/region	Patients (n)	RNA prevalence	Seroprevalence	Comment	Ref.
Liver transplant; 1997-2017	Japan	313	14.1%	/	No significant association between HPgV infection and liver transplant outcomes; HPgV infection induced the up-regulation of ISG expression in peripheral blood mononuclear cells	Izumi <i>et al</i> [27], 2019
Renal transplant; 1989-1996	Italy	155	24%	17%	Not associated with disease pathogenicity; Lower serum levels of HCV-RNA in HGV/HCV co-infected carriers compared to those infected with HCV only	De Filippi <i>et al</i> [34], 2001
Renal transplant; 2015-2016	Brazil	61	36.1%	/	Most common genotype 2 (80.9%), followed by G3 (9.5%), G1 (4.85), and G5 (4.8%); no significant impact on patient outcomes	Savassi-Ribas <i>et al</i> [31], 2020
Renal transplant	France	103 HCV positive RT recipients	28%	/	HGV infection has no detrimental effect on liver enzymes or liver histology in HCV-positive patients	Rostaing <i>et al</i> [37], 1999
Heart transplant; 1993-1998	Germany	51 transplant candidates	2.0%; 0	0; 6.0%	RNA persisted after transplant; anti-E2 antibodies persisted after transplant	Kallinowski <i>et al</i> [38], 2002
		Post-transplant	36.0% <i>de novo</i>	/	RNA persisted in 94% infected patients; No significant correlation between the number of blood transfusions and the infection; No impact on liver disease or patient outcome	
Liver transplant; 1993-1998	Germany	72 transplant candidates	11.%	/	RNA persisted in 88% of infected patients	Kallinowski <i>et al</i> [38], 2002
		Post-transplant	36% <i>de novo</i>	/	RNA persisted in 87% of infected patients; no significant correlation between the number of blood transfusions and the infection; no impact on liver disease or patient outcome	
Kidney transplant; 1997	Thailand	94	43%	/	Co-circulation of HGV and HCV RNA was detected in 12 patients (13%)	Raengsakulrach <i>et al</i> [30], 1997
Heart transplant; 1993-1996	Germany	243	24%	/	HGV infections are transfusion related; not related to the use of mechanical circulatory assist devices or immunosuppression	Wolff <i>et al</i> [36], 1996
Liver transplant; 1989-1996	Germany	98	Pre-tx 8.2%; post-tx 44%	/	None of the hepatitis B, hepatitis C, or fulminant hepatitis, were HGV-RNA positive preoperatively; HGV was frequently acquired after LT but had no impact on the short- and medium-term clinical course post-LT	Fischer <i>et al</i> [23], 1999
Liver transplant; 2007-2010	Iran	106	9.4%	/	Moderate prevalence of HGV infection in liver transplant recipients	Ebadi <i>et al</i> [39], 2011
Kidney transplant; 1986-1990	United States	93	12%	/	HGV infection does not adversely affect clinical outcome during early follow-up	Isaacson <i>et al</i> [32], 1999
Liver transplant; 1989-1996	Italy	136	Pre-tx 18.4%; post-tx 47.8%	Pre-tx 26.5%	Liver transplant patients are heavily exposed to HGV before and after transplantation; HGV does not induce liver disease; most infections are self-limited and induce a protective immunity (anti-E2 antibodies presence)	Silini <i>et al</i> [40], 1998
HSCT; 1985-1996	France	95	29.5%	/	Acute GVHD, chronic GVHD, or veno-occlusive disease are similar in HGV+ and HGV- recipients in early period after allogenic BMT	Corbi <i>et al</i> [21], 1997
Kidney transplant; 1997	Germany	221	14%	40%	The majority of infected individuals eliminate the virus over time	Stark <i>et al</i> [33], 1997
Kidney transplant; NA	Turkey	69	42%	/	Genotype 2 is the dominant type; subgroup 2a most common of the isolates	Erensoy <i>et al</i> [41], 2002

Liver transplant; 1993-1995	United Kingdom	47	47%	/	HGV does not cause significant liver disease after LT	Karayiannis <i>et al</i> [42], 1998
Liver transplant; 1979-1990	Netherlands	39	Pre-tx 15.4%; post-tx 43.6%	/	HGV infection is highly prevalent in liver transplant patients; in the absence of HBV or HCV co-infection with, no long-term negative influence on the graft	Haagsma <i>et al</i> [24], 1997
Kidney transplant; 1997-2000	India	70	52.9%	58.6%	GBV-C/HGV RNA significantly associated with ≥ 20 hemodialysis sessions	Abraham <i>et al</i> [29], 2003
Liver transplant; 1990-1994	United States	179	Pre-tx 15%; post-tx 50%	/	HGV infection not associated with poor outcome	Hoofnagle <i>et al</i> [26], 1997
HSCT; 2011-2017	China	188	18.6%	/	HPgV is highly prevalent in HSCT patients; blood transfusions significantly increase the risk of HPgV infection	Li <i>et al</i> [22], 2019
HSCT; 2014-2015	Switzerland	40	35%	/	HPgV is highly prevalent and persists for several months	Vu <i>et al</i> [20], 2019

HBV: Hepatitis B virus; HCV: Hepatitis C virus; HGV: Hepatitis G virus; HSCT: Hematopoietic stem cell transplantation; HpgV: Human pegivirus; GBV-C: GB virus C; GVHD: Graft *versus* host disease; BMT: Bone marrow transplantation; ISG: Interferon-stimulated gene.

REFERENCES

- 1 **Thijssen M**, Tacke F, Beller L, Deboutte W, Yinda KC, Nevens F, Laleman W, Van Ranst M, Pourkarim MR. Clinical relevance of plasma virome dynamics in liver transplant recipients. *EBioMedicine* 2020; **60**: 103009 [PMID: 32979836 DOI: 10.1016/j.ebiom.2020.103009]
- 2 **Legoff J**, Michonneau D, Socie G. The virome in hematology-Stem cell transplantation and beyond. *Semin Hematol* 2020; **57**: 19-25 [PMID: 32690140 DOI: 10.1053/j.seminhematol.2020.05.001]
- 3 **Thézé J**, Lowes S, Parker J, Pybus OG. Evolutionary and Phylogenetic Analysis of the Hepaciviruses and Pegiviruses. *Genome Biol Evol* 2015; **7**: 2996-3008 [PMID: 26494702 DOI: 10.1093/gbe/evv202]
- 4 **International Committee on Taxonomy of Viruses**. Genus: Pegivirus. [cited 24 October 2020]. Available from: https://talk.ictvonline.org/ictv-reports/ictv_online_report/positive-sense-rna-viruses/w/flaviviridae/363/genus-pegivirus
- 5 **Kapoor A**, Kumar A, Simmonds P, Bhuvu N, Singh Chauhan L, Lee B, Sall AA, Jin Z, Morse SS, Shaz B, Burbelo PD, Lipkin WI. Virome Analysis of Transfusion Recipients Reveals a Novel Human Virus That Shares Genomic Features with Hepaciviruses and Pegiviruses. *mBio* 2015; **6**: e01466-e01415 [PMID: 26396247 DOI: 10.1128/mBio.01466-15]
- 6 **Chivero ET**, Stapleton JT. Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection. *J Gen Virol* 2015; **96**: 1521-1532 [PMID: 25667328 DOI: 10.1099/vir.0.000086]
- 7 **Marano G**, Franchini M, Farina B, Piccinini V, Pupella S, Vaglio S, Grazzini G, Liumbruno GM. The human pegivirus: A new name for an "ancient" virus. Can transfusion medicine come up with something new? *Acta Virol* 2017; **61**: 401-412 [PMID: 29186957 DOI: 10.4149/av_2017_402]
- 8 **Berg MG**, Lee D, Collier K, Frankel M, Aronsohn A, Cheng K, Forberg K, Marcinkus M, Naccache SN, Dawson G, Brennan C, Jensen DM, Hackett J Jr, Chiu CY. Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. *PLoS Pathog* 2015; **11**: e1005325 [PMID: 26658760 DOI: 10.1371/journal.ppat.1005325]
- 9 **Wang H**, Wan Z, Sun Q, Zhu N, Li T, Ren X, An X, Deng S, Wu Y, Li X, Li L, Li J, Tong Y, Tang S. Second Human Pegivirus in Hepatitis C Virus-Infected and Hepatitis C Virus/HIV-1-Co-infected Persons Who Inject Drugs, China. *Emerg Infect Dis* 2018; **24**: 908-911 [PMID: 29664364 DOI: 10.3201/eid2405.161162]
- 10 **Wan Z**, Liu J, Hu F, Shui J, Li L, Wang H, Tang X, Hu C, Liang Y, Zhou Y, Cai W, Tang S. Evidence that the second human pegivirus (HPgV-2) is primarily a lymphotropic virus and can replicate independent of HCV replication. *Emerg Microbes Infect* 2020; **9**: 485-495 [PMID: 32100631 DOI: 10.1080/22221751.2020.1730247]
- 11 **Carson JL**, Triulzi DJ, Ness PM. Indications for and Adverse Effects of Red-Cell Transfusion. *N Engl J Med* 2017; **377**: 1261-1272 [PMID: 28953438 DOI: 10.1056/NEJMra1612789]
- 12 **Mohr EL**, Stapleton JT. GB virus type C interactions with HIV: the role of envelope glycoproteins. *J Viral Hepat* 2009; **16**: 757-768 [PMID: 19758271 DOI: 10.1111/j.1365-2893.2009.01194.x]
- 13 **Bhattarai N**, Stapleton JT. GB virus C: the good boy virus? *Trends Microbiol* 2012; **20**: 124-130 [PMID: 22325031 DOI: 10.1016/j.tim.2012.01.004]
- 14 **Vahidnia F**, Petersen M, Stapleton JT, Rutherford GW, Busch M, Custer B. Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. *Clin Infect Dis* 2012; **55**: 1012-1019 [PMID: 22752515 DOI: 10.1093/cid/cis589]
- 15 **Tillmann HL**, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Goergen B, Detmer

- J, McMorro M, Stoll M, Schmidt RE, Manns MP. Infection with GB virus C and reduced mortality among HIV-infected patients. *N Engl J Med* 2001; **345**: 715-724 [PMID: [11547740](#) DOI: [10.1056/NEJMoa010398](#)]
- 16 **Lauck M**, Bailey AL, Andersen KG, Goldberg TL, Sabeti PC, O'Connor DH. GB virus C coinfections in west African Ebola patients. *J Virol* 2015; **89**: 2425-2429 [PMID: [25473056](#) DOI: [10.1128/JVI.02752-14](#)]
- 17 **N'Guessan KF**, Boyce C, Kwara A, Archampong TNA, Lartey M, Sagoe KW, Kenu E, Obo-Akwa A, Blackard JT. Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). *Virus Genes* 2018; **54**: 361-367 [PMID: [29551002](#) DOI: [10.1007/s11262-018-1555-2](#)]
- 18 **Fama A**, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, Ansell SM, Liebow M, Xiang J, Maurer MJ, Slager SL, Nowakowski GS, Stapleton JT, Cerhan JR. Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. *Clin Infect Dis* 2020; **71**: 1221-1228 [PMID: [31671178](#) DOI: [10.1093/cid/ciz940](#)]
- 19 **Chang CM**, Stapleton JT, Klinzman D, McLinden JH, Purdue MP, Katki HA, Engels EA. GBV-C infection and risk of NHL among U.S. adults. *Cancer Res* 2014; **74**: 5553-5560 [PMID: [25115299](#) DOI: [10.1158/0008-5472.CAN-14-0209](#)]
- 20 **Vu DL**, Cordey S, Simonetta F, Brito F, Docquier M, Turin L, van Delden C, Boely E, Dantin C, Pradier A, Roosnek E, Chalandon Y, Zdobnov EM, Masouridi-Levrat S, Kaiser L. Human pegivirus persistence in human blood virome after allogeneic haematopoietic stem-cell transplantation. *Clin Microbiol Infect* 2019; **25**: 225-232 [PMID: [29787887](#) DOI: [10.1016/j.cmi.2018.05.004](#)]
- 21 **Corbi C**, Traineau R, Esperou H, Ravera N, Portelette E, Benbunan M, Gluckman E, Loiseau P. Prevalence and clinical features of hepatitis G virus infection in bone marrow allograft recipients. *Bone Marrow Transplant* 1997; **20**: 965-968 [PMID: [9422476](#) DOI: [10.1038/sj.bmt.1701005](#)]
- 22 **Li Z**, Li Y, Liang Y, Hu L, Chen S. Prevalence and risk factors of human pegivirus type 1 infection in hematopoietic stem cell transplantation patients. *Int J Infect Dis* 2019; **85**: 111-113 [PMID: [31170546](#) DOI: [10.1016/j.ijid.2019.05.032](#)]
- 23 **Fischer L**, Sterneck M, Feucht HH, Schuhmacher C, Malagó M, Rogiers X, Laufs R, Broelsch CE. Hepatitis G virus infection in liver transplant recipients. *Transplant Proc* 1999; **31**: 496-499 [PMID: [10083208](#) DOI: [10.1016/s0041-1345\(98\)01726-6](#)]
- 24 **Haagsma EB**, Cuypers HT, Gouw AS, Sjerps MC, Huizenga JR, Slooff MJ, Jansen PL. High prevalence of hepatitis G virus after liver transplantation without apparent influence on long-term graft function. *J Hepatol* 1997; **26**: 921-925 [PMID: [9126808](#) DOI: [10.1016/s0168-8278\(97\)80261-9](#)]
- 25 **Cotler SJ**, Gretch DR, Bronner MP, Tateyama H, Emond MJ, dela Rosa C, Perkins JD, Carithers RL Jr. Hepatitis G virus co-infection does not alter the course of recurrent hepatitis C virus infection in liver transplantation recipients. *Hepatology* 1997; **26**: 432-436 [PMID: [9252155](#) DOI: [10.1002/hep.510260225](#)]
- 26 **Hoofnagle JH**, Lombardero M, Wei Y, Everhart J, Wiesner R, Zetterman R, Yun AJ, Yang L, Kim JP. Hepatitis G virus infection before and after liver transplantation. Liver Transplantation Database. *Liver Transpl Surg* 1997; **3**: 578-585 [PMID: [9404956](#) DOI: [10.1002/lt.500030604](#)]
- 27 **Izumi T**, Sakata K, Okuzaki D, Inokuchi S, Tamura T, Motooka D, Nakamura S, Ono C, Shimokawa M, Matsuura Y, Mori M, Fukuhara T, Yoshizumi T. Characterization of human pegivirus infection in liver transplantation recipients. *J Med Virol* 2019; **91**: 2093-2100 [PMID: [31350911](#) DOI: [10.1002/jmv.25555](#)]
- 28 **Adams MJ**, King AM, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2013). *Arch Virol* 2013; **158**: 2023-2030 [PMID: [23580178](#) DOI: [10.1007/s00705-013-1688-5](#)]
- 29 **Abraham P**, John GT, Raghuraman S, Radhakrishnan S, Thomas PP, Jacob CK, Sridharan G. GB virus C/hepatitis G virus and TT virus infections among high risk renal transplant recipients in India. *J Clin Virol* 2003; **28**: 59-69 [PMID: [12927752](#) DOI: [10.1016/s1386-6532\(02\)00239-1](#)]
- 30 **Raengsakulrach B**, Ong-aj-yooth L, Thaiprasert T, Nilwarangkur S, Ong-aj-yooth S, Narupiti S, Thirawuth V, Klungthong C, Snitbhan R, Vaughn DW. High prevalence of hepatitis G viremia among kidney transplant patients in Thailand. *J Med Virol* 1997; **53**: 162-166 [PMID: [9334928](#) DOI: [10.1002/\(sici\)1096-9071\(199710\)53:2<162::aid-jmv9>3.0.co;2-7](#)]
- 31 **Savassi-Ribas F**, Pereira JG, Horta MAP, Wagner TCS, Matuck TA, Monteiro de Carvalho DB, Mello FCA, Varella RB, Soares CC. Human pegivirus-1 infection in kidney transplant recipients: A single-center experience. *J Med Virol* 2020 [PMID: [32167183](#) DOI: [10.1002/jmv.25764](#)]
- 32 **Isaacson AH**, Bhardwaj B, Qian K, Davis GL, Kato T, Mizokami M, Lau JY. Hepatitis G virus infection in renal transplant recipients. *J Viral Hepat* 1999; **6**: 151-160 [PMID: [10607227](#) DOI: [10.1046/j.1365-2893.1999.00149.x](#)]
- 33 **Stark K**, Meyer CG, Tacke M, Schwarz A, Braun C, Huzly D, Engel AM, May J, Bienzle U. Hepatitis G virus RNA and hepatitis G virus antibodies in renal transplant recipients: prevalence and risk factors. *Transplantation* 1997; **64**: 608-612 [PMID: [9293874](#) DOI: [10.1097/00007890-199708270-00011](#)]
- 34 **De Filippi F**, Lampertico P, Soffredini R, Rumi MG, Lunghi G, Aroldi A, Tarantino A, Ponticelli C, Colombo M. High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients. *Dig Liver Dis* 2001; **33**: 477-479 [PMID: [11572574](#) DOI: [10.1016/s1590-8658\(01\)80025-6](#)]
- 35 **Kallinowski B**, Janicki M, Seelig R, Seipp S, Hagel J, Dengler T, Schnitzler P, Theilmann L, Stremmel W. Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients. *J*

- Heart Lung Transplant* 1999; **18**: 190-193 [PMID: 10328143 DOI: 10.1016/s1053-2498(98)00034-5]
- 36 **Wolff D**, Körner MM, Wolff C, Körfer R, Kleesiek K. Transfusion-related hepatitis G virus infections in heart transplant recipients. *Transplantation* 1996; **62**: 1697-1698 [PMID: 8970636 DOI: 10.1097/00007890-199612150-00034]
- 37 **Rostaing L**, Izopet J, Arnaud C, Cisterne JM, Alric L, Rumeau JL, Duffaut M, Durand D. Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. *Transplantation* 1999; **67**: 556-560 [PMID: 10071027 DOI: 10.1097/00007890-199902270-00012]
- 38 **Kallinowski B**, Seipp S, Dengler T, Klar E, Theilmann L, Stremmel W. Clinical impact of hepatitis G virus infection in heart and liver transplant recipients. *Transplant Proc* 2002; **34**: 2288-2291 [PMID: 12270402 DOI: 10.1016/s0041-1345(02)03239-6]
- 39 **Ebadi M**, Yaghobi R, Geramizadeh B, Bahmani MK, Malek-Hosseini SA, Nemayandeh M. Prevalence of HCV and HGV infections in Iranian liver transplant recipients. *Transplant Proc* 2011; **43**: 618-620 [PMID: 21440779 DOI: 10.1016/j.transproceed.2011.01.066]
- 40 **Silini E**, Belli L, Alberti AB, Asti M, Cerino A, Bissolati M, Rondinara G, De Carlis L, Forti D, Mondelli MU, Ideo G. HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. *J Hepatol* 1998; **29**: 533-540 [PMID: 9824261 DOI: 10.1016/s0168-8278(98)80147-5]
- 41 **Erensoy S**, Zeytinoglu A, Göksel S, Ozacar T, Ozkahya M, Ok E, Tuumlarkoglu S, Bilgiç A. GB virus C/hepatitis G virus infection among renal transplant recipients in Izmir, Turkey: Molecular analysis of phylogenetic groups. *Int J Infect Dis* 2002; **6**: 242-243 [PMID: 12718845 DOI: 10.1016/s1201-9712(02)90121-9]
- 42 **Karayiannis P**, Brind AM, Pickering J, Mathew J, Burt AD, Hess G, Bassendine MF, Thomas HC. Hepatitis G virus does not cause significant liver disease after liver transplantation. *J Viral Hepat* 1998; **5**: 35-42 [PMID: 9493515 DOI: 10.1046/j.1365-2893.1998.00078.x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

